Chongqing Pharscin Pharmaceutical Co Ltd Tangible Net Worth Ratio
Chongqing Pharscin Pharmaceutical Co Ltd tangible net worth ratio. Chongqing Pharscin Pharmaceutical Co Ltd (002907) has a Tangible Net Worth Ratio of 85.8% as of September 2025. This metric is calculated by deducting intangible assets (CN¥242.40 Million) from net assets (CN¥1.71 Billion) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. Check 002907 strategic asset allocation to assess the company's strategic physical and investment asset allocation.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Tangible Net Worth Ratio of Chongqing Pharscin Pharmaceutical Co Ltd (2013–2024)
Tangible net worth ratio of Chongqing Pharscin Pharmaceutical Co Ltd from 2013 to 2024. This chart shows how Chongqing Pharscin Pharmaceutical Co Ltd's Tangible Net Worth Ratio has changed across 12 annual periods from 2013 to 2024. As of September 2025, the ratio stands at 85.8%, reflecting net assets of CN¥1.71 Billion with intangible assets of CN¥242.40 Million CNY. See working capital to net assets of Chongqing Pharscin Pharmaceutical Co Ltd to evaluate short-term liquidity relative to the company's equity base.
Chongqing Pharscin Pharmaceutical Co Ltd Tangible Net Worth Ratio by Year (2013–2024)
Chongqing Pharscin Pharmaceutical Co Ltd tangible net worth ratio by year from 2013 to 2024. The table below presents the year-by-year Tangible Net Worth Ratio for Chongqing Pharscin Pharmaceutical Co Ltd from 2013 to 2024, covering 12 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For live market cap and overall valuation, see Chongqing Pharscin Pharmaceutical Co Ltd (002907) total market value.
| Year | Tangible NW Ratio | Net Assets (CNY) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 90.6% | CN¥1.66 Billion | CN¥156.16 Million | CN¥1.92 Billion | ▲ +0.4 pp |
| 2023 | 90.2% | CN¥1.62 Billion | CN¥158.94 Million | CN¥1.85 Billion | ▼ -2.7 pp |
| 2022 | 92.8% | CN¥1.61 Billion | CN¥115.22 Million | CN¥1.87 Billion | ▲ +0.7 pp |
| 2021 | 92.1% | CN¥1.27 Billion | CN¥99.72 Million | CN¥1.77 Billion | ▼ -1.6 pp |
| 2020 | 93.8% | CN¥1.18 Billion | CN¥73.66 Million | CN¥1.72 Billion | ▲ +1.0 pp |
| 2019 | 92.7% | CN¥1.07 Billion | CN¥77.63 Million | CN¥1.64 Billion | ▲ +1.9 pp |
| 2018 | 90.8% | CN¥828.91 Million | CN¥76.23 Million | CN¥1.09 Billion | ▲ +1.4 pp |
| 2017 | 89.4% | CN¥719.95 Million | CN¥75.98 Million | CN¥885.15 Million | ▲ +6.3 pp |
| 2016 | 83.1% | CN¥461.42 Million | CN¥77.92 Million | CN¥652.32 Million | ▲ +0.2 pp |
| 2015 | 82.9% | CN¥365.71 Million | CN¥62.39 Million | CN¥539.29 Million | ▼ -7.2 pp |
| 2014 | 90.1% | CN¥299.77 Million | CN¥29.57 Million | CN¥537.39 Million | ▲ +2.7 pp |
| 2013 | 87.5% | CN¥240.97 Million | CN¥30.18 Million | CN¥415.35 Million | — |